Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKU CNSX:BUX NYSE:CRL TSE:EDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$155.32-1.1%$160.27$91.86▼$230.02$7.65B1.47774,769 shs1.28 million shsEDTSpectral MedicalC$1.48C$1.17C$0.46▼C$1.84C$423.01M0.246437100,911 shs55,868 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International0.00%+1.36%+0.51%+5.39%-24.58%EDTSpectral Medical0.00%-12.94%+17.46%+70.11%+127.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$155.32-1.1%$160.27$91.86▼$230.02$7.65B1.47774,769 shs1.28 million shsEDTSpectral MedicalC$1.48C$1.17C$0.46▼C$1.84C$423.01M0.246437100,911 shs55,868 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International0.00%+1.36%+0.51%+5.39%-24.58%EDTSpectral Medical0.00%-12.94%+17.46%+70.11%+127.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ABUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.31Hold$177.0714.00% UpsideEDTSpectral Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BUX, CRL, EDT, and AKU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025CRLCharles River Laboratories InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$142.00 ➝ $195.008/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$180.00 ➝ $190.008/7/2025CRLCharles River Laboratories InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$145.00 ➝ $160.008/7/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$155.00 ➝ $165.007/9/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$170.00 ➝ $180.007/9/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$150.00 ➝ $200.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00BUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.89$21.69 per share7.16$67.80 per share2.29EDTSpectral MedicalC$2.53M167.07C$0.02 per share82.50C($0.08) per share-18.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/ABUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$1.33N/A14.124.15-1.69%15.74%7.09%11/5/2025 (Estimated)EDTSpectral Medical-C$18.68M-C$0.07N/A∞N/AN/A-973.97%-93.22%N/ALatest BUX, CRL, EDT, and AKU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CRLCharles River Laboratories International$2.50$3.12+$0.62$1.06$983.76 million$1.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEDTSpectral MedicalN/A1.45%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99BUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.691.361.10EDTSpectral Medical26.030.610.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%EDTSpectral Medical0.03%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%EDTSpectral Medical18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International20,10049.21 million48.57 millionOptionableEDTSpectral Medical29285.82 millionN/ANot OptionableBUX, CRL, EDT, and AKU HeadlinesRecent News About These CompaniesSpectral Medical (TSE:EDT) Share Price Passes Above 50 Day Moving Average - Here's WhySeptember 8, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Share Price Crosses Above Fifty Day Moving Average - Time to Sell?August 31, 2025 | marketbeat.comSpectral Medical is a stock to buy now, this analyst saysAugust 26, 2025 | cantechletter.comCSpectral Medical Secures US$3 Million Funding to Advance Sepsis TreatmentAugust 25, 2025 | tipranks.comSpectral Medical eyes US approval of endotoxic septic shock deviceAugust 13, 2025 | finance.yahoo.comSpectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic ShockAugust 12, 2025 | finance.yahoo.comSpectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)August 10, 2025 | uk.finance.yahoo.comSpectral Medical Inc.: Spectral Medical Announces Second Quarter and Provides Corporate UpdateAugust 9, 2025 | finanznachrichten.deSpectral Medical Files Base Shelf Prospectus for Financial FlexibilityJuly 4, 2025 | tipranks.comSpectral Medical Inc. Announces Filing of Base Shelf ProspectusJuly 4, 2025 | financialpost.comFSpectral Medical Inc. (EDT.TO) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSpectral Medical is “fundamentally undervalued”, Paradigm saysMay 9, 2025 | cantechletter.comCSpectral Medical Inc.: Spectral Medical Announces First Quarter and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deSpectral Medical Inc.: Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with VantiveMay 7, 2025 | finanznachrichten.deSpectral Medical Full Year 2024 Earnings: Beats ExpectationsMarch 29, 2025 | finance.yahoo.comStocks in play: Spectral Medical Inc.March 27, 2025 | ca.finance.yahoo.comSpectral Medical Advances Amid Tigris Trial ChallengesDecember 3, 2024 | markets.businessinsider.comThe top TSX healthcare stocks under $1November 5, 2024 | msn.comSpectral Medical Nears Completion of Tigris TrialNovember 4, 2024 | markets.businessinsider.comSpectral announces last patient out in U.S. burn pivotal study at Burns CenterOctober 30, 2024 | markets.businessinsider.comSpectral AI Names Company Founder As Its New Board ChairmanOctober 19, 2024 | dallasinnovates.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Can Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025BUX, CRL, EDT, and AKU Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.Biomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$155.32 -1.67 (-1.06%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$155.39 +0.07 (+0.05%) As of 09/19/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Spectral Medical TSE:EDTC$1.48 0.00 (0.00%) As of 09/19/2025 04:00 PM EasternSpectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
